---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093941"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:06:08.738383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical Q2 commercial revenue record $15.1M (+29%); FY24 guide $68-70M

## Summary
- Commercial revenue $15.1M (+29% YoY); gross margin 86.2% (up 500 bps).
- Net loss $15.4M ($0.60 loss per share) vs $10.4M loss ($0.41) in Q2 2023.
- RECELL GO PMA approved May 29; RECELL GO mini submitted June 28, FDA decision by Dec 27.
- Exclusive distribution deal with Regenity for dermal matrix; 510(k) clearance expected Q4 2024.
- Q3 2024 revenue guidance $19-20M (40-48% YoY growth); FY24 guide revised to $68-70M (37-41% growth).

## SEC filing metadata
- accession: 0000950170-24-093941
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/0000950170-24-093941-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000095017024093941/rcel-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093941
- JSON: https://secwatch.observer/filing/0000950170-24-093941.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093941.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.